Use for BRD4 protein degradation inducing compound

WO2026205300A1PCT designated stage Publication Date: 2026-10-01TANABE PHARMA CORP

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: PCT/JP2026/012292
Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2025-08-29
Filing Date: 2026-03-26
Publication Date: 2026-10-01

Application Information

Patent Timeline

29 Aug 2025

Priority

26 Mar 2026

Application

PCT/JP2026/012292

01 Oct 2026

Publication

WO2026205300A1

IPC: A61K31/551; A61K31/496; A61K31/706; A61K45/00; A61P35/00; A61P35/02; A61P43/00; C07D495/14

Inventors: OOIKE SHINSUKE; KURITA TAKASHI

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Smart Images

Figure JPOXMLDOC01-APPB-C000001
Figure JPOXMLDOC01-APPB-C000002
Figure JPOXMLDOC01-APPB-C000003

Patent Text Reader

Abstract

The present invention addresses the problem of providing: a novel combination of anticancer agents that makes it possible to markedly shrink or reduce cancer via a synergistic anticancer effect; and a therapeutic agent for rare cancer.　The present invention provides a pharmaceutical composition, a combination with another compound, a kit, a method for treatment and / or prevention of cancer, and a method for treatment and / or prevention of rare cancer, each being characterized in that a specific BRD4 protein degradation inducing compound is used.

Need to check novelty before this filing date? Find Prior Art